Eli Lilly falls as Wave weight-loss drug misses analyst expectations
Orforglipron's 12.4% weight loss falls short of Wall Street targets, raising questions about oral GLP-1 market potential
Eli Lilly shares fell sharply on Thursday after the company's oral weight-loss drug candidate orforglipron failed to meet Wall Street expectations in a pivotal Phase 3 trial, raising fresh questions about the commercial potential of oral alternatives to blockbuster injectable obesity treatments.
The Indianapolis-based pharmaceutical giant reported that patients receiving the highest dose of orforglipron lost an average of 12.4% of their body weight, or 27.3 pounds, over 72 weeks in the ATTAIN-1 trial. The results fell short of investor expectations that the drug would achieve 15% to 21% weight loss, comparable to injectable treatments like Eli Lilly's own Zepbound and Novo Nordisk's Wegovy, which have set the current clinical standard.
Eli Lilly shares were trading at $916.31, down from their 50-day moving average of $1018, with the relative strength index at 37, indicating the stock has entered oversold territory. Despite the day's decline, the company retains a market capitalization of $808 billion and has delivered 51.4% year-over-year earnings growth in its most recent quarter.
"The magnitude of weight loss, while clinically meaningful, appears to be below the efficacy threshold that investors had been hoping for," said analysts following the trial readout. "This creates near-term uncertainty around the oral GLP-1 franchise even as Eli Lilly's injectable portfolio continues to dominate the obesity market."
The disappointment with orforglipron contrasts sharply with the performance of Eli Lilly's retatrutide, a "triple-G" candidate that targets three gut hormones. In March 2026, Eli Lilly announced that retatrutide met the primary endpoints of a Phase 3 study in patients with Type 2 diabetes, with participants in the highest dose group losing an average of 15% of body weight over 40 weeks. Earlier Phase 3 data released in January 2026 demonstrated an average weight loss of 28.7%, setting what analysts described as a new clinical standard.
Eli Lilly has already submitted a new drug application for orforglipron to the FDA for use in adults with obesity, with a decision anticipated by March 2026. A separate Phase 3 study, ATTAIN-MAINTAIN, demonstrated that orforglipron offered significant weight maintenance benefits for patients transitioning from injectable GLP-1 receptor agonists, suggesting the drug may still find a niche in the treatment landscape.
The company's fundamentals remain robust by pharmaceutical industry standards. Eli Lilly reported trailing twelve-month revenue of $65.2 billion with a profit margin of 31.7% and operating margin of 44.9%. The stock currently trades at a price-to-earnings ratio of 39.68 based on trailing results, with a forward P/E of 26.45.
Wall Street analysts maintain an overwhelmingly positive outlook on the stock, with 24 of 31 analysts rating it a buy or strong buy, compared to 6 hold ratings and 1 strong sell. The consensus price target stands at $1,209.34, suggesting significant upside potential even after the recent decline.
The obesity drug market has become increasingly competitive, with both Eli Lilly and Novo Nordisk racing to develop treatments that offer improved efficacy, convenience, or dosing profiles. While injectable GLP-1 agonists have dominated the market to date, oral formulations represent a potentially massive opportunity if they can demonstrate comparable efficacy with greater patient convenience.
Eli Lilly's Zepbound (tirzepatide) and Mounjaro have established the company as a leader in the GLP-1 space, driving the stock's 52-week high of $1,132.06 earlier this year. However, the market has become increasingly sensitive to clinical data readouts, with investors scrutinizing each trial for signs of competitive advantages or setbacks.
"The key question now is whether oral GLP-1s can capture meaningful market share given the efficacy gap versus injectables," said healthcare sector analysts. "Weight maintenance data and patient preference studies will be critical in determining orforglipron's commercial trajectory."
Looking ahead, investors will focus on the FDA decision on orforglipron in March 2026, additional Phase 3 data for retatrutide, and ongoing clinical trials across Eli Lilly's broader pipeline. The company's ability to diversify beyond its injectable GLP-1 franchise while maintaining growth in its core diabetes and oncology businesses will be closely watched.